Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa.

Autor:	Choi D; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL., McDonald B; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL., Rubin DT; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.
Jazyk:	angličtina
Zdroj:	ACG case reports journal [ACG Case Rep J] 2024 Nov 06; Vol. 11 (11), pp. e01546. Date of Electronic Publication: 2024 Nov 06 (Print Publication: 2024).
DOI:	10.14309/crj.0000000000001546
Abstrakt:	Risankizumab-rzaa (RZA) is a fully human immunoglobulin G monoclonal antibody (Mab) which has fewer immunogenic concerns compared with chimeric Mabs. The pivotal trials of RZA found no significant differences in infusion reactions between drug and placebo. This case illustrates successful transition to subcutaneous RZA following a serious hypersensitivity reaction to intravenous RZA. (© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu